See more : Startech Labs, Inc. (LAAB) Income Statement Analysis – Financial Results
Complete financial analysis of Endexx Corporation (EDXC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Endexx Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Omni-Lite Industries Canada Inc. (OLNCF) Income Statement Analysis – Financial Results
- Tecan Group AG (TCHBF) Income Statement Analysis – Financial Results
- Shyamkamal Investments Limited (SHYMINV.BO) Income Statement Analysis – Financial Results
- Huaizhong Health Group, Inc. (ADAD) Income Statement Analysis – Financial Results
- Mining, Minerals & Metals plc (MMM.L) Income Statement Analysis – Financial Results
Endexx Corporation (EDXC)
About Endexx Corporation
Endexx Corporation engages in the manufacturing and sale of cannabidiol (CBD)-based products for the health and wellness market. It provides CBD creams, oils, capsules, extracts, topicals, drinks, chocolates, and pet products, as well as hemp-derived health and beauty care products for supporting the therapeutic relief of pain and inflammation for humans and pets through its e-commerce site cbdunlimited.com, as well as other online and in-store retailers. The company was formerly known as CBD Unlimited, Inc. and changed its name to Endexx Corporation in May 2020. Endexx Corporation is headquartered in Cave Creek, Arizona.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.91M | 1.28M | 650.52K | 1.97M | 1.50M | 797.55K | 418.39K | 220.76K | 126.26K | 34.64K | 0.00 |
Cost of Revenue | 5.06M | 774.57K | 994.59K | 606.62K | 823.58K | 449.25K | 212.46K | 166.54K | 115.72K | 732.00 | 0.00 |
Gross Profit | -1.15M | 503.01K | -344.08K | 1.36M | 674.49K | 348.30K | 205.93K | 54.22K | 10.54K | 33.91K | 0.00 |
Gross Profit Ratio | -29.39% | 39.37% | -52.89% | 69.22% | 45.02% | 43.67% | 49.22% | 24.56% | 8.35% | 97.89% | 0.00% |
Research & Development | 5.25K | 27.07K | 10.15K | 15.27K | 20.72K | 43.64K | 8.11K | 18.74K | 57.47K | 115.99K | 2.00K |
General & Administrative | 0.00 | 3.25M | 3.22M | 3.50M | 3.30M | 1.06M | 449.88K | 763.69K | 879.84K | 533.87K | 234.70K |
Selling & Marketing | 0.00 | 564.08K | 1.78M | 445.14K | 255.90K | 108.10K | 52.27K | 41.83K | 36.97K | 59.38K | 0.00 |
SG&A | 4.09M | 3.82M | 5.00M | 3.95M | 3.30M | 1.17M | 502.14K | 805.53K | 916.82K | 593.25K | 234.70K |
Other Expenses | 0.00 | 20.61K | 20.40K | 15.45K | 25.18K | 65.05K | 2.64K | 2.64K | 67.72K | 35.78K | -599.00 |
Operating Expenses | 4.09M | 3.87M | 5.03M | 3.98M | 3.35M | 1.22M | 512.90K | 826.92K | 976.72K | 710.32K | 237.07K |
Cost & Expenses | 9.15M | 4.64M | 6.02M | 4.59M | 4.17M | 1.67M | 725.36K | 993.45K | 1.09M | 710.32K | 237.07K |
Interest Income | 0.00 | 1.24M | 950.55K | 3.13M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 |
Interest Expense | 3.80M | 1.24M | 950.55K | 3.13M | 1.90M | 435.72K | 306.75K | 3.97K | 270.99K | 2.00 | 0.00 |
Depreciation & Amortization | 9.67K | 20.61K | 20.40K | 15.45K | 17.42K | 10.64K | 2.64K | 2.64K | 2.43K | 1.08K | -374.00 |
EBITDA | -4.67M | -3.65M | -5.37M | -5.73M | -6.78M | -1.33M | -276.13K | -770.05K | -896.03K | -674.60K | -236.70K |
EBITDA Ratio | -119.45% | -352.65% | -1,020.65% | -146.48% | -585.00% | -100.28% | -72.74% | -348.83% | -709.65% | -2,616.83% | 0.00% |
Operating Income | -5.24M | -3.36M | -5.37M | -2.62M | -2.67M | -867.48K | -306.97K | -772.70K | -966.18K | -675.68K | -237.07K |
Operating Income Ratio | -134.08% | -263.17% | -825.70% | -132.73% | -178.50% | -108.77% | -73.37% | -350.02% | -765.21% | -1,950.57% | 0.00% |
Total Other Income/Expenses | -3.23M | -1.23M | -1.44M | -5.45M | -3.99M | -1.63M | -361.76K | -3.97K | -84.16K | 267.66K | -599.00 |
Income Before Tax | -8.47M | -4.13M | -6.81M | -8.06M | -9.66M | -1.74M | -668.73K | -776.66K | -1.17M | -408.02K | -237.67K |
Income Before Tax Ratio | -216.81% | -323.19% | -1,046.58% | -409.01% | -644.73% | -217.94% | -159.83% | -351.82% | -926.20% | -1,177.88% | 0.00% |
Income Tax Expense | -1.98M | 766.71K | 950.55K | 3.13M | 1.73M | -434.95K | 306.75K | -1.00 | 338.71K | -231.87K | 747.00 |
Net Income | -6.50M | -4.90M | -7.76M | -11.19M | -11.39M | -1.74M | -668.73K | -776.66K | -1.17M | -408.02K | -237.67K |
Net Income Ratio | -166.26% | -383.20% | -1,192.70% | -567.92% | -760.28% | -217.94% | -159.83% | -351.82% | -926.20% | -1,177.89% | 0.00% |
EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
EPS Diluted | -0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
Weighted Avg Shares Out | 504.71M | 503.98M | 455.05M | 379.17M | 343.49M | 289.10M | 259.70M | 235.54M | 216.32M | 211.71M | 199.04M |
Weighted Avg Shares Out (Dil) | 504.71M | 503.98M | 455.05M | 379.17M | 343.49M | 289.10M | 262.47M | 235.54M | 216.32M | 211.71M | 199.04M |
Endexx's non-nicotine vape company acquisition sees revenue soaring in fiscal 1Q
Endexx receives US$3.8M order for its HYLA vape product from customers in Italy
Endexx receives HYLA vape product orders totalling $2.3M in revenue for 1H 2023
Endexx achieves distribution registration for its hemp and CBD products in 4 key US states
Endexx reveals 4Q accomplishments; expands Amazon and international product distribution
Endexx Corporation says its HYLA division receives purchase orders for over 200,000 vape-delivery product units
Endexx Corporation says new subsidiary HYLA looks to expand into eight new markets
Endexx Corp announces acquisition of controlling stake in nicotine-free vape producer Hyla
Endexx Corp says its Blesswell premium skincare line for men is now available via Amazon.com
Endexx sees fiscal 3Q revenue rise by 246% with strong expansion into mass retail stores
Source: https://incomestatements.info
Category: Stock Reports